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Abstract
Background and Aims: Parenteral nutrition (PN) has be-
come an efficient, safe, and convenient treatment over years 
for patients suffering from intestinal failure. Home PN (HPN) 
enables the patients to have a high quality of life in their own 
environment. The therapy management however implies 
many restrictions and potentially severe lethal complica-
tions. Prevention and therapy of the latter are therefore of 
utmost importance. This study aims to assess and character-
ize the situation of patients with HPN focusing on prevalence 
of catheter-related complications and mortality. Methods: 
Swiss multicentre prospective observational study collect-
ing demographic, anthropometric, and catheter-related 
data by means of questionnaires every sixth month from 
2017 to 2019 (24 months), focusing on survival and compli-
cations. Data were analysed using descriptive statistics. Lo-
gistic regression models were fitted to investigate associa-
tion between infection and potential co-factors. Results: 
Seventy adult patients (50% women) on HPN were included 
(≈5 patients/million adult inhabitants/year). The most com-
mon underlying diseases were cancer (23%), bariatric sur-
gery (11%), and Crohn’s disease (10%). The most prevalent 
indication was short bowel syndrome (30%). During the 
study period, 47% of the patients were weaned off PN; mor-
tality rate reached 7% for a median treatment duration of 
1.31 years. The rate of catheter-related infection was 
0.66/1,000 catheter-days (0.28/catheter-year) while the rate 
of central venous thrombosis was 0.13/1,000 catheter-days 
(0.05/catheter-year). Conclusion: This prospective study 
gives a comprehensive overview of the adult Swiss HPN pa-
tient population. The collected data are prerequisite for eval-
uation, comparison, and improvement of recommendations 
to ensure best treatment quality and safety.
© 2021 S. Karger AG, Basel
Introduction
The European Society for Clinical Nutrition and Me-
tabolism (ESPEN) defines parenteral nutrition (PN) as “a 
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administration of nutrients such as amino acids, glucose, 
lipids, electrolytes, vitamins, and trace elements” [1]. Ac-
cording to the ESPEN guidelines, home PN (HPN) is in-
dicated in those patients who are unable to meet their 
nutritional requirements via the oral and/or enteral route 
and who can be safely managed outside the hospital [2]. 
Furthermore, HPN should be prescribed as the primary 
and life-saving therapy for patients with transient-revers-
ible or permanent-irreversible chronic intestinal failure 
due to non-malignant or malignant disease [2, 3].
Owing to pharmaceutical and technical progress, this 
complex and multifaceted treatment has become effi-
cient, effective, safe, and convenient [2]. In the long-term 
care, it may be used in an ambulatory setting, for example, 
at home, where patients practice better their daily life ac-
tivities and have good or reasonably good quality of life 
in their usual environment. HPN additionally contrib-
utes to prevent prolonged hospital stays and readmis-
sions resulting in reduced healthcare costs [4–7]. High-
quality equipment and outstanding medical as well as lo-
gistic support contribute to minimize risks and to improve 
HPN patients’ outcome, since safety and quality assur-
ance are of central relevance [4, 8, 9]. Complications re-
lated to HPN treatment are manifold, rather frequent and 
potentially life threatening (Table 1). Adequate preven-
tion and rapid management of these complications are 
therefore of paramount importance.
In Switzerland as in many other countries, very few 
studies on patients with HPN have been conducted. Data 
on these patients rarely exist owing to the rarity of the 
treatment (rare disease frequency 1:2,000) and to the high 
heterogeneity of the patient population [10, 11]. Further, 
there is no national registry allowing representative ob-
servation of developments in this population, as well as 
international comparability and benchmarking of stan-
dards of care.
This study aims to assess and characterize the situation 
of adult patients with HPN in Switzerland regarding clin-
ical aspects and focusing on the prevalence of catheter-
related complications and mortality. Further, the objec-
tive is to identify factors, which are potentially associated 
with treatment outcome, to evaluate and optimize the 
treatment quality and to ensure patients’ safety and better 
address their problems. It additionally may contribute to 
define evidence-based measures to optimize treatment 
and care in the HPN population.
Methods
Study Design and Data Collection
This prospective multicentre observational study was conduct-
ed in Switzerland over 24 months, from January 1, 2017, until Jan-
uary 1, 2019. Data were collected using questionnaires distributed 
to the patients and their treating physicians in charge of PN (i.e., 
general practitioner or hospital physician depending on the local 
setting). These questionnaires (available as supplementary mate-
rial) were created by an international group of experts and previ-
ously validated in a pilot trial and focused on catheters and related 
complications (mechanic and metabolic). They contained items 
on patient demographics (sex, age, nationality, and living/working 
situation), medical history, medication, detailed nutritional regi-
men, anthropometric changes (body weight and BMI), and tech-
nical-related aspects of catheters (type, aseptic handling, and care). 
These questionnaires were filled in at baseline and follow-up ques-
tionnaires every 6 months.
Patient Selection and Inclusion Criteria
Adult patients (≥18 years old) with HPN for an estimated 
period >3 weeks, started at least 7 days prior to the study inclu-
sion, not critically ill, not in a terminal phase (estimated life ex-
pectancy >30 days), and without severe psychological problems, 
Table 1. Overview of the complications related to the HPN [12]
Medical/metabolic complications Over/underfeeding, hyperglycaemia, refeeding syndrome, hypertriglyceridemia, cholestasis, 
intestinal failure-associated liver disease and non-alcoholic steatohepatitis, intestinal and renal 
complications, osteopathy, reduced immune competency
Hygienic complications Complex catheter care, infection, sepsis
Technic/mechanic complications Complex handling (attaching and removing parenteral admixtures and installing infusion 
pump), occlusion, central venous thrombosis, displacement, breaking, incompatibility, 
instability, and contamination of parenteral admixtures
Psychologic complications Fear of complications, depression
Somatic complications Physical problems, fatigue, diarrhoea, polyuria, pain
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addiction, or dementia were included in the study. To this end, 
community and hospital physicians whose names were accessi-
ble through the official Swiss Association for Common Tasks of 
Health Insurers (SVK) taking care of HPN patients were con-
tacted. Patients were subsequently contacted, screened for inclu-
sion and exclusion criteria, and included in the study. This pro-
cedure was always conducted by the same single investigator, 
experienced in PN and in clinical study conduction. Patients 
were additionally asked for their further consent, allowing the 
investigator to collect medical data from the treating physician. 
Inquiry was regularly repeated to include all new patients on 
HPN during the study period.
Included patients filled the questionnaire alone or in a person-
al interview with the local investigator (mean duration 40 min) at 
home, during a hospital stay, or an outpatient visit. The question-
naires were available in German, French, Italian, and English. 
Deaths occurring during the study period were reported by family 
members and confirmed by the treating physician. The question-
naires completed by the patient prior to death were included in the 
final analysis and the PN duration accordingly adjusted.
Statistics
Statistical analysis was performed with Stata 14.0 (StataCorp. 
2015. Stata Statistical Software: Release 14: StataCorp LP; College 
Station, TX, USA). Results are presented as mean ± standard de-
viation (MV±SD), or as number (n) and percentage (%). The Fish-
er’s exact test for categorical variables was used for data analysis. 
Logistic regression models were fitted to investigate the associa-
tion between the infections occurred during the entire study pe-
riod and potential co-factors at baseline. No data were excluded 
from statistical calculations. As the sample size (n = 70) and the 
number of events (n = 20) were rather small, we did not calculate 
multivariable models but single models for each of the co-factors 
and infection. The p values <0.05 were considered as statistically 
significant.
Ethical Statement
This study was conducted in accordance with the ethical guide-
lines of the 1957 Declaration of Helsinki and the current national 
laws. The Bernese Cantonal Ethics Committee approved this study 
(KEK Bern, Study No. 2016-00669). Patients gave their written in-
formed consent.
Results
In total, 70 patients were included in the study, repre-
senting 39,514 catheter-days (92 catheter-years). The 
mean follow-up duration was 11.3 months. Roughly 63% 
(n = 44) were cared and medically supervised at the Bern 
University Hospital. The prevalence of HPN in the adult 
Swiss population (6,835,622 million in 2019) amounts 
5/million adult inhabitants per year. The incidence of PN 
is 3/million inhabitants per year. Figure 1 shows the de-
tailed study flowchart. Table 2 shows the baseline charac-
teristics of the study population.
Indication for HPN and Underlying Disease
Table 3 shows the indications for prescribing HPN and 
the most common underlying diseases of the included pa-
tients. Of this population, 75% suffer from benign and 
25% from malignant diseases. Further, 40% (n = 28) had 
a stoma, of which 28% (n = 7) with related problems (e.g., 
stoma fluid/bag leakage).
HPN Regimen and Medication
Half of the patients (n = 35) were started on HPN dur-
ing the course of the study. Overall, 5 (7%) patients had 
total PN and 4 patients (6%) made the transition from 
total PN to supplemental PN during the study period. 
Table  4 shows the HPN regimen characteristics of the 
patients. The median duration of HPN was 1.31 years 
(range 25 days–37 years). In total, 47% of the patients 
(n = 33) were weaned off HPN: 26 resumed oral nutrition 
(thereof 7 had colostomy reversal) and 7 were in a termi-
Follow-up 24 months
(n = 9)
  4 joined late
12 stopped home parenteral nutrition
  3 died
  4 withdrew consent
  1 lost for follow-up









19 stopped home parenteral nutrition
  1 died
  1 withdrew consent
  1 lost for follow-up
  6 joined late
  1 stopped home parenteral nutrition
  1 died
  3 withdrew consent
  1 lost for follow-up
  2 joined late
Fig. 1. Study flowchart. Joined late means patients were included after 
the study start and were therefore not able to complete more follow-up 
questionnaires; withdrew consent means that the patients did not want 
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nal condition (mean 14.5 days). Thirteen percent (n = 9) 
of the patients were diabetics and received insulin thera-
py. Commonly used drugs were gastric acid inhibitors 
(70%, n = 49), analgesics (43%, n = 30), enzyme replace-
ment therapy (27%, n = 19), motility activators (20%, 
n = 14), antidepressants (17%, n = 12), and diuretics 
(10%, n = 7).
Central Venous Catheters, Catheter Care, and Related 
Complications
Table 5 shows CVC characteristics. Port-a-cath needle 
change occurred in average every 9.1 ± 3.2 days (range: 
4–14 days). Dressing mostly consisted of films 84% (n = 
59), mulls 7% (n = 5), or a mix of both 8% (n = 6). Dress-
ing change occurred in average every 5.9 ± 2.7 days.
Fifty-six percent (n = 39) of the patients took care of 
themselves or with the help of a family member of the PN 
(aseptic handling, attach and depend the admixture, and 
add the micronutrients) while 44% (n = 31) required sup-
port from home nurses. The training for the catheter han-
dling usually took place before leaving the hospital 
through the nursing staff (41%, n = 29). In most cases 
(74%, n = 52), initial training was described as too short, 
while 10% (n = 7) of the patients reported no specific 
training. Patients commonly received written informa-
tion, mainly from the treating medical hospital staff (n = 
16).
Most patients (80%, n = 56) reported to have an ex-
plicit setting up of the PN, in a specific place in the house 
(78%, n = 55): 23% (n = 16) in the living room, 20% (n = 
14) in the bedroom, 17% (n = 12) in the kitchen/eating 
room, while 18% (n = 13) had separate dedicated places. 
Surface disinfection was reported by 94% (n = 66) of the 
patients, of which 17% (n = 12) used sterile towels. The 
most widely used skin disinfectant was chlorhexidine 
31% (n = 22), and the most widely used surface disinfec-
tant was alcohol. The aseptic handling occurred after a 
hand washing procedure in 88% (n = 62), hand disinfec-
Table 2. Population’s baseline characteristics
Baseline characteristics N (%)















With partner 36 (52)
With children <18 years 6 (9)






Vocational certificate 3 (4)
University/technical school 16 (23)
n/a 4 (6)
Working status
Full time 5 (7)
Part time 9 (13)
Housework 2 (3)
Not possible any more 24 (34)
Retired 28 (40)
n/a 2 (3)
Table 3. Indication for HPN and underlying disease, according to 
the pathophysiological classification of intestinal failure [3]
N (%)
Indication for PN
Short bowel syndrome 21 (30)
Motility disorder 13 (19)
Severe malnutrition 12 (17)
Fistula 11 (16)
Mucosal disease 6 (9)




Bariatric surgery 8 (11)
Crohn’s disease 7 (10)
Mesenteric infarction 5 (7)
Surgical complications (chyle leak, leaking 
anastomosis, etc.) 4 (6)
Pancreatic disease 4 (6)
CIPO 4 (6)
Radiation enteritis 3 (4)
Others (polymyositis, protein losing enteropathy, 
common variable immunodeficiency, 
M. Hirschprung, FAP Gardner syndrome, etc.) 16 (23)
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tion in 98% (n = 69), with one-way gloves in 64% (n = 
45), and with hygiene masks in 54% (n = 38) of the pa-
tients.
A large majority of the patients (88%, n = 62) were hos-
pitalized in the half year prior to the study inclusion, 40% 
(n = 28) in relation to HPN. The hospital stay average was 
27.8 ± 33.3 days (median: 13.5 days). During the study, 
the hospital stay averaged 26.1 ± 32.4 days (median: 13.5 
days). Catheter-related problems caused not elective hos-
pitalization in 57% of the cases. The number of PN and 
catheter-related incidents amounts 0.98/1,000 catheter-
days (0.42/catheter-year). Table  6 shows the complica-
tion that occurred since the start of HPN (baseline) and 
during the course of the study (2 years).
Most common signs of infection were fever 73% (n = 
19), shivering 69% (n = 18), redness of the skin at the cath-
eter site 38% (n = 10), pus 31% (n = 8), feeling unwell 23% 
(n = 6), and hypertonia 7% (n = 2). Table 7 shows the odds 
ratios (OR) for infection during the course of the study 
according to observed co-factors. Of all observed co-fac-
tors, only handling of the PN/CVC revealed a significant 
association, when handling by a home nurse resulted in a 
significantly reduced OR for infection as compared with 
the self-carers (OR = 0.31, 95% CI: 0.10–0.98, p = 0.045).
Death occurred in 7% (n = 5) of the patients during the 
2-year study period. Mortality was due to the underlying 
disease and not related to any complication of the HPN 
in all cases.
Table 4. HPN regimen
Total PN, n (%) 5 (7)
Combination of EN (ONS or tube feeding) and PN, n (%) 4 (6)
Combination of oral nutrition and PN, n (%) 61 (87)
Standard industrial all-in-one admixture, n (%) 68 (97)
Nocturnal administration, n (%) 65 (93)
Average administration duration, h 13.2±3.3
Administration days per week, d 5.4±1.8
Mean total energy per applied bag, kcal 1,520±442
Mean total energy per kg body weight, kcal 24.1±8.1
Additional fluid requirements, n (%) 25 (36)
Isotonic sodium chloride 0.9% solution, n (%) 17 (24)
Ringer’s solution, n (%) 5 (7)
Bicarbonate 8.4% solution, n (%) 2 (3)
Administration days per week, d 5.5±2.2
Vitamins and trace elements addition to PN admixture, n (%) 67 (96)
Supplemental electrolytes added to PN admixture, n (%) 10 (14)
Potassium, n (%) 6 (8)
Magnesium, n (%) 5 (7)
HPN, home parenteral nutrition.






Single-lumen catheters 66 (94)
Placement side
Right side 35 (50)
Insertion vein
Subclavian vein 22 (31)
Cephalic vein 17 (24)
Jugular vein 16 (23)
Use





Isotonic saline solutions 35 (50)
Heparin block (500 IU) 15 (22)
Taurolidine block (taurolidine citrate 4%) 18 (26)
Taurolidine-heparin block (taurolidine citrate 
4% and heparin 100 IU) 2 (3)
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Discussion/Conclusion
This is the first prospective study investigating a Swiss 
adult cohort of patients on HPN [10, 11]. Despite its rather 
small sample size, this study is representative of this popula-
tion. The incidence and prevalence of HPN (3 and 5/million 
adult inhabitants, respectively) reported in this study are 
comparable to previous studies. In Europe, the incidence of 
HPN reaches about 4–6 per million per year, and in Swit-
zerland 4 per 1 million adult inhabitants per year were pre-
viously reported, while the prevalence of HPN reaches 2–40 
per million adult inhabitants in Europe and 4–6 per million 
adult inhabitants in Switzerland [4, 10, 11].
Crohn’s disease, mesenteric infarction, and cancer are 
amongst the most common underlying diseases for HPN 
in Europe [4]. While cancer remains the most common 
underlying disease in the present study, we also included 
several patients after bariatric surgery [4]. This increas-
ingly becomes a new indication for HPN due the high 
frequency of this surgical intervention and associated 
complications [13, 14]. Regarding the indications, short 
bowel syndrome remains the most common one [2, 8, 9, 
15, 16].
The overall survival rate after the 2-year study pe-
riod was 93%. This is comparable to other studies after 
1 year [5, 8]. Similar to other studies, the cause of death 
was the underlying disease rather than PN-related 
complications [6, 7, 17]. Weaning off rates of HPN in 
our cohort was 47%, similar to the rates reported in the 
literature (20–50%) [2, 14, 18, 19]. Our weaning data 
are high considering the greater proportion of malig-
nant diseases compared to published data, despite the 
low number of very long-term HPN patients. We 
grouped patients with malignant and benign diseases 
regarding the small overall sample size what may rep-
resent a bias given the intrinsic difference in prognosis, 
rate of complications such as infections and thrombo-
sis, etc.
We found overall a high compliance of the HPN 
management with the current ESPEN guidelines on 
HPN [2]. The catheter features were mainly in line with 
the guidelines regarding type of catheters, insertion 
site, dressing, and care. The loss of venous access (e.g., 
catheter displacement and site shift) is the main prob-
lem in HPN treatment [7]. Catheter-related infections 
are the most common as well as dangerous complica-
tions with an overall infection rate of 0.66 per 1,000 
catheter-days in our study, defined as proposed in the 
ESPEN guidelines on PN [20]. Other studies reported 
rates between 0.38 and 4.58/1,000 catheter-days [7, 21, 
22]. Around 80% of the infections are catheter-related 
bloodstream, 17% are exit site, and 2% are tunnel infec-
tions [7]. Due to the nature of the study, we could only 
record the infections for which catheter had to be re-
moved and were not able to differentiate between the 
different types of infections. Other infections may have 
been missed, for example, infections where catheters 
were saved. Restricting only to catheter-related blood-
stream infections would result in lower rates (presum-
ing that catheter-related bloodstream infections ac-
count for 80% of the total infections: 0.52/1,000 cathe-
ter-days). However, the terminology to define these 
infections is still a matter of debate, and it makes it dif-
ficult to compare trials [23]. We were not able to detect 
any significant specific pattern influencing infection 
rates in our study. This is probably mainly due to the 
limited sample size of our study, which did not allow us 
to calculate multivariable and thus adjusted regres-
sions. With larger samples at hand, observed trends and 
associations would become clearer. Since infections are 
largely caused by skin pathogens (50%), hygiene and 
aseptic training remain the key to reduce infection rates 
and thus morbidity and mortality rates and costs [2, 
Table 6. Occurrence of catheter-related complications
During study period, n (%)
















One infection 15 (21)
Two infections 4 (6)
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Table 7. Odds ratios for infection




50–65 yr 0.20 0.05–0.82 0.026
>65 yr 0.33 0.09–1.17 0.087
Educational level
Others 1.00
Higher education 0.58 0.11–3.02 0.521
Living status
Others 1.00
Live alone 0.44 0.13–1.53 0.199
Disease-related parameters
Presence of a stoma
No 1.00
Yes 2.33 0.80–6.77 0.119
Underlying disease
Cancer 1.00
Inflammatory disease 0.50 0.08–3.29 0.471
Obstructive disease 1.00 0.17–5.77 1.000
Others 1.08 0.26–4.42 0.918
Surgical complications 0.46 0.09–2.41 0.359
PN-related parameters
Care centre
Practicing physician 0.33 0.04–2.95 0.323
Canton hospital 1.17 0.30–4.47 0.822
University hospital 1.00
Handling of the PN/CVC
Self-carer 1.00
Home nurse 0.31 0.10–0.98 0.045
Duration of PN
≤1 yr 1.00
2–5 yr 1.05 0.33–3.39 0.932
>5 yr 1.02 0.25–4.11 0.975
Type of CVC
Hickmann catheter 1.00
Port-a-cath 0.58 0.17–1.93 0.373
PICC 0.37 0.07–1.94 0.240
Lock of CVC
NaCl 1.00
Heparin 2.06 0.52–8.16 0.302
Tauro lock 1.98 0.60–6.56 0.263
Use of CVC
Blood withdrawal 1.00
No blood withdrawal 1.56 0.51–4.73 0.436
Hand washing procedure before disinfection
No 1.00
Yes 3.09 0.36–26.92 0.306
Use of gloves for aseptic handling
No 1.00




Yes 2.63 0.76–9.15 0.128
Occurrence of mechanic complication
No 1.00
Yes 1.45 0.51–4.17 0.486
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23]. The use of a taurolidine lock was not associated 
with reduced infection rates in our cohort. However, 
from our clinical practice in the hospital as well as long-
term expertise in the field, we noted subjectively a trend 
of less catheter-related infections since the implemen-
tation of taurolidine lock. The efficacy of taurolidine 
has been demonstrated as well in the primary preven-
tion of catheter-related infections as in the secondary 
prophylaxis; however, most of the trials present meth-
odological weakness [24–26]. A further important as-
pect for the investigated quality and safety of HPN was 
thrombosis, which might closely be related to infec-
tions. We found very low rates of CVC-associated 
thrombosis (0.05/catheter-year) compared to the litera-
ture (0.08/catheter-year) despite the 25% of our cohort 
suffering from malignancies (higher risk of thrombo-
embolism: 25 vs. 10%) [6, 8, 27, 28].
In our study, the overall complication rate amounts 
0.98/1,000 catheter-days, affecting 28% of the patients. 
While similar percentages were found in other studies, 
the rates were higher with 1.06–5.06 events per 1,000 
catheter-days [21, 27, 29]. According to a recent meta-
analysis of prospective trials, the current evidence is 
insufficient to show differences in infection rates be-
tween tunnelled catheters and peripherally inserted 
central catheters while the latter shows lower infection 
rates compared to port systems [30]. Furthermore, 
there were no differences in the rates of mechanical 
complications and catheter-related thrombosis. Vashi 
et al. [31] also could not show any difference between 
catheter types and postulated that the incidence of in-
fections in patients receiving HPN might be related to 
the care protocol used rather than to the type of cath-
eter. Catheter-related infection rates effectively reflect 
the quality of training and the adherence of patients to 
the given instructions. Our results are in line with 
these findings, as we could not show any difference 
between the types of catheters by overall low compli-
cation rates.
We found discrepancies with the current ESPEN HPN 
guidelines in 2 points: blood drawing from the catheter 
and lowering of the infusion rates in the last hour of ad-
ministration [2]. In our cohort, the routine drawing of 
blood samples occurs via the catheters in 63%, which 
should be avoided as far as possible due to a higher com-
plication risk. Further, none of the patients reduced the 
infusion rate at the end of the mostly overnight PN admin-
istration, meant to avoid rebound hypoglycaemia due to 
the high insulin stimulation by the important glucose dos-
ing by PN [2]. Only one patient in our study reported hy-
poglycaemia, what she could manage by eating small por-
tions of carbohydrate-rich food. Since PN was supple-
mental in the large majority of the patients, they may have 
eaten after the administration, thus avoiding rebound hy-
poglycaemia. To give evidence, this statement should be 
investigated by appropriate blood sugar monitoring in an 
appropriately powered group of HPN patients.
The current guidelines and standards recommend the 
prescription, implementation, and monitoring of PN by 
multi-professional nutritional support teams in dedicated 
competence centres with expertise in management of 
HPN, including physicians, specialized nurses, dieticians, 
and pharmacists [2, 32]. Patients cared by such centres 
show better clinical outcomes [2]. Evidence-based stan-
dards and well-documented complication reports are 
therefore mandatory for a quality-assured HPN provi-
sion. Our study showed that HPN programs are not im-
plemented in all hospitals and that the management of the 
patients varies to a large extent offering important poten-
tial for improvement, for example, implementing stan-
dardized protocols, conducting educational meetings, 
networking, and expert opinion exchange between hospi-
tals and competence centres [18]. Our results also under-
line the importance of education and training for aseptic 
handling, since self-caring patients showed higher risk for 
infection compared to the nurses. Further, there is urgen-
cy for a nationwide registry for PN to characterize and as-
sess quality of care in HPN and for international compa-
rability and benchmarking. Our results show low compli-
cation rates, which do not influence mortality rates. Even 
if the management of HPN largely varies throughout the 
country, the compliance with the current ESPEN guide-
lines is high and validates their clinical value, contributing 
to high standard of care and low complication rates.
Best practices for HPN remain to be defined, as they 
are mostly based on expert opinion, expertise, experience, 
and local/national/international guidelines [16]. There-
fore and in order to offer all patients the best therapy, 
there is a clear need to define competence centres and 
adequately staff trained and experienced for (H)PN with 
personnel with PN.
This study also has limitations. First, results are sub-
jected to reporting and recall bias since we used question-
naires to collect data. Second, it is mostly difficult for pa-
tients to keep apart the complications or issues related to 
underlying disease and specifically related to HPN. In 
conclusion, this study underlines that when administered 
according to the actual standards, the HPN therapy is 
safe, efficient, and enables patients to live at home in fa-
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